Comparative Pharmacology
Head-to-head clinical analysis: FENOFIBRIC ACID versus OMACOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOFIBRIC ACID versus OMACOR.
FENOFIBRIC ACID vs OMACOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibric acid is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and clearance of triglyceride-rich lipoproteins and reduces apolipoprotein C-III production, leading to decreased triglycerides and increased HDL cholesterol.
Omega-3-acid ethyl esters (EPA and DHA) reduce hepatic triglyceride synthesis by inhibiting acyl-CoA:1,2-diacylglycerol acyltransferase and increasing beta-oxidation. They also decrease very-low-density lipoprotein (VLDL) secretion and enhance triglyceride clearance from circulating VLDL particles.
135 mg orally once daily
4 g orally once daily or 2 g orally twice daily, taken with meals. Each capsule contains 1 g of omega-3-acid ethyl esters (approximately 465 mg eicosapentaenoic acid and 375 mg docosahexaenoic acid).
None Documented
None Documented
Clinical Note
moderateFenofibric acid + Cyclosporine
"Fenofibric acid may increase the nephrotoxic activities of Cyclosporine."
Clinical Note
moderateFenofibric acid + Raltegravir
"Fenofibric acid may increase the myopathic rhabdomyolysis activities of Raltegravir."
Clinical Note
moderateFenofibric acid + Chenodeoxycholic acid
"The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Fenofibric acid."
Clinical Note
moderateFenofibric acid + Ursodeoxycholic acid
Terminal elimination half-life is approximately 20 hours (range 15-25 h) for fenofibric acid, supporting once-daily dosing. In renal impairment, half-life may be prolonged.
Terminal elimination half-life: ~55–75 hours for EPA and DHA (beta-phase). Clinical context: steady-state achieved after 4–8 weeks; half-life supports once-daily dosing.
Primarily renal as unchanged drug and glucuronide conjugate (approximately 60-70% of dose); remainder eliminated via biliary/fecal routes (~25%).
Primarily fecal as unchanged drug and metabolites; <5% renal. Biliary excretion accounts for ~90% of elimination via feces, with minimal urinary excretion (0.5–2%).
Category C
Category C
Antilipemic
Antilipemic
"The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibric acid."